Loading clinical trials...
Loading clinical trials...
A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies
Conditions
Interventions
Thymoglobulin
Fludarabine
+6 more
Locations
3
United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Saint-Louis Hospital
Paris, France
St Mary's Hospital
London, United Kingdom
Start Date
May 1, 2013
Primary Completion Date
November 1, 2023
Completion Date
December 31, 2024
Last Updated
January 10, 2024
NCT05170412
NCT06526117
NCT06665997
NCT07431398
NCT07222475
NCT05377372
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions